Elanco and WEDterinary Collaborate to Develop Novel Therapies for Pets
Shots:
- Elanco & WEDterinary LLC have entered into a research agreement to develop novel therapies for pets
- As per the agreement, Elanco will fund the research via its R&D operating expenses
- First phase of the collaboration will focus on targeted gene therapy for chronic kidney diseases in cats & explore new research areas to extend pets’ lifespan
Ref: Elanco | Image: Elanco
Related News:- Medgene collaborates with Elanco for H5N1 Cattle Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
